viewClinigen Group PLC

Clinigen unveils latest addition to medicine cabinet and says trading was in line with market forecasts

In an update, the speciality pharma company told investors it was acquiring the global rights to Proleukin for an undisclosed sum from Novartis

medicines cabinet
Cancer drug Proleukin is being added to the Clinigen product line

Clinigen Group PLC (LON:CLIN) added a new product to its expanding medicine cupboard and said its business was growing in line with market forecasts.

In an update, the speciality pharma company told investors it was acquiring the rights outside the US to Proleukin for an undisclosed sum from Novartis.

The drug is used to treat the metastatic forms of renal cell carcinoma and melanoma and the plan is to work with the healthcare professionals to revitalise the product.

One future deployment could see Proleukin used in combination with other drugs. Trials in this regard are currently being carried out.

WATCH: Clinigen CEO on significant opportunities for new drug

Updating on its recent trading, Clinigen told investors revenues for the year ended June 30 grew by 27% on a constant currency basis, while gross profit advanced by 16% on the same measurement. Underlying earnings (EBITDA) are likely to grow at a faster pace than gross profits.

The group said the commercial medicines arm continued to deliver “excellent growth”, which helped offset a weaker showing from the clinical trial services business, which strengthened in the second half.

Two key acquisitions made during the year just gone – Quantum and IMMC - are bedding in well, Clinigen reported.

Chief executive Shaun Chilton said: "With a strong balance sheet and cash generative business model, our strategy remains to drive growth across our portfolio organically, by making acquisitions and through geographic expansion."

City broker repeats 'buy' advice

The shares, up 15% in the last month, succumbed to a bout of light profit-taking as they fell 2% to 974.5p each.

Peel Hunt said it remained a ‘buyer’ of the stock up to 1,350p, meaning the price would have to advance almost 40% to hit that target.

The City broker said Clinigen is on an “undemanding” earnings multiple currently. It added: “We believe the product acquisition news should drive the stock up, despite the relatively robust performance into this update.”

Quick facts: Clinigen Group PLC

Price: 610.55 GBX

Market: AIM
Market Cap: £812.21 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...


West Wits Mining boss hails big boost to resource at Witwatersrand Basin Project

West Wits Mining Limited's (ASX:WWI) Jac van Heerden speaks to Proactive's Andrew Scott after announcing they've grown the gold resource at the Witwatersrand Basin Project (WBP) in South Africa by 700,000 ounces to 4.37 million ounces at 3.88 g/t gold. The lift in resources and 0.48 g/t increase...

17 minutes ago

2 min read